Attending the American Diabetes Association’s Scientific Sessions as patients certainly affords us a unique window into progress on diabetes tools and devices, clinical research, and cure research. But what about the health professionals for whom this conference was actually designed?…
read more
AtheroGenics, Inc. (NASDAQ: AGIX) announced that data from its 6,144-patient ARISE Phase 3 clinical study of AGI-1067 (succinobucol) were presented at the 68th Scientific Sessions of the American Diabetes Association (ADA) in San Fr... Read Post
In a new post-hoc analysis based on the American Association of Clinical Endocrinologists (AACE/ACE) diabetes algorithm presented at the American Diabetes Association (ADA) 71st Annual Scientific Sessions, significantly more patient... Read Post
VeroScience, in collaboration with S2 Therapeutics, announced the presentation of clinical and preclinical data at the American Diabetes Association (ADA) 69th Scientific Sessions on Cycloset, a novel treatment for patients with Typ... Read Post